| Drug General Information |
| Drug ID |
D08MXP
|
| Former ID |
DIB001419
|
| Drug Name |
LEE011
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 3 |
[1],
[2]
|
|---|
| Company |
Novartis AG
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H30N8O
|
| InChIKey |
RHXHGRAEPCAFML-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
87793394, 120110003, 138555830, 140717308, 175444442, 178103955, 196411464, 198983029, 198993418, 210275346, 210280994, 223370367, 223404354, 223405967, 224379035, 226642892, 247056333, 249814497, 252148259, 252160882, 252215684, 252451787, 252472287, 252543483
|
| Target and Pathway |
| Target(s) |
Cell division protein kinase 4 |
Target Info |
Modulator |
[3]
|
|---|
| Cell division protein kinase 6 |
Target Info |
Modulator |
[3]
|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Tight junction
|
|
T cell receptor signaling pathway
|
|
Hepatitis B
|
|
Measles
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Pancreatic cancer
|
|
Glioma
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancerhsa04110:Cell cycle
|
|
MicroRNAs in cancer
|
|
Non-small cell lung cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Validated targets of C-MYC transcriptional activation
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of retinoblastoma proteinp73pathway:p73 transcription factor network
|
|
Coregulation of Androgen receptor activity
|
|
C-MYB transcription factor network
|
|
IL2 signaling events mediated by STAT5
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Oxidative Stress Induced Senescence
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Oncogene Induced Senescence
|
|
RMTs methylate histone arginines
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Ubiquitin-dependent degradation of Cyclin D1
|
|
Cyclin D associated events in G1
|
|
Meiotic recombinationR-HSA-2559580:Oxidative Stress Induced Senescence
|
|
WikiPathways
|
DNA Damage Response
|
|
G1 to S cell cycle control
|
|
Ovarian Infertility Genes
|
|
PPAR Alpha Pathway
|
|
Bladder Cancer
|
|
S Phase
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Meiotic Recombination
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
|
Wnt Signaling Pathway Netpath
|
|
Metastatic brain tumor
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
miRNAs involved in DNA damage response
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01958021) Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2). U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7383). |
|---|
| REF 3 | Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. |
|---|
